.png)
.png)
.png)
Want to learn how to optimize your processes?
Discover our solutions for companies in the pharmaceutical and chemical industry
In brief: The Central and Eastern European pharma market is expanding fast, but in Hungary output is flat while headcount keeps growing — and the fix isn't hiring more people, it's getting more efficient. Fragmented, traditional procurement processes carry real hidden costs: supplier onboarding that drags on for months, maverick spend, lost volume discounts, and compliance risks that surface during a GxP audit. This article covers three reasons procurement now belongs on the executive agenda: supply chain fragility, the wave of patent losses piling up through 2030, and the fact that AI is only as good as the data feeding it.
Procurement has traditionally lived in the back office: a necessary evil, tolerated rather than celebrated. It rarely makes the CEO's first agenda item — and that's understandable.
But there's a problem with that thinking. While you're working out how to protect your company from the next supply chain crisis, how to get new products to market faster, and how to get more out of your team without hiring fifty more people, your procurement department might be losing a critical GMP certificate in an Excel spreadsheet somewhere right now.
Welcome to one of modern pharma's biggest challenges: procurement is no longer a back-office function. It could be the backbone of tomorrow's competitiveness.
The Central and Eastern European pharma market is the growth engine of the European region. While Western markets slow down, the CEE region is expanding fast enough that investors are pouring into Poland, Hungary, and the Czech Republic.
But here's what makes the Hungarian situation particularly interesting: output is flat while headcount keeps rising. The Hungarian pharma industry has one of the highest shares of skilled knowledge workers in domestic manufacturing — professionals whose hourly rates far exceed the manufacturing average. And the vacancy rate has climbed noticeably in recent years.
Translate that into CEO terms: you won't be able to keep hiring indefinitely. And even if you could, that alone wouldn't solve the productivity problem. So what's left? Automation. Efficiency. And cutting out the processes that eat up time that should go toward strategic work.
Take a typical case: onboarding a new API supplier. It sounds simple. Here's what it usually looks like in practice:
This cycle isn't just slow. It's actively dangerous. And the most painful part: it's normal.
Maverick spend: when the official procurement system is too slow or too cumbersome, people work around it. That means losing out on meaningful volume discounts and letting in suppliers nobody has vetted for GMP compliance.
Long cycle times: after rolling out modern platforms, users typically report meaningful, often double-digit, cuts to cycle times. In pharma, where every day counts, a one-month delay in procurement can push a product launch back by months. Work out what that means in lost revenue for a product close to marketing authorization.
Hidden compliance risk: this is the real ticking time bomb. A GMP-noncompliant raw material bought from a supplier that wasn't properly vetted can trigger a product recall. The direct costs are substantial, and the reputational damage is hard to put a number on.
Learn more about the hidden cost of procurement.
The biggest invisible problem is the chaos of outdated systems. A typical scenario: the ERP system says the supplier is active. Quality assurance keeps a list of approved suppliers in a SharePoint folder. Procurement tracks contracts in a separate spreadsheet. Legal has its own system. And when an urgent purchase comes up, nobody's quite sure which version reflects reality.
Decisions slow down. Before every procurement decision, someone has to manually pull information together from five or six different places. A simple question — "which supplier should we buy from?" — turns into someone's weekend project.
Mistakes become inevitable. When people manually copy data from one system to another, errors creep in sooner or later. And in pharma, a mistyped batch number or expiry date isn't just an administrative slip — it's a compliance incident.
Visibility stays an illusion. You think you can see your supplier risks because there's a monthly report. But that report was built from data that's already weeks old, pulled together manually by three different people. By the time you see it, the problem has already happened.
What happens when a rigid, outdated procurement system can't handle an urgent, non-standard request? People find a way around it.
Need urgent clinical trial material? "I'll just sort it out by email." Need to work with a new, innovative supplier who doesn't fit the standard categories? "We'll make a workaround." Need special terms with a strategic partner? "Legal will handle that separately."
And suddenly, the exceptions stop being exceptions. This becomes the rule. The official system only covers routine purchases; everything unusual, high-value, or strategically risky happens outside it. That's when leadership loses control without even realizing it.
Supply chain fragility has stayed near the top of corporate risk lists in recent years, ahead of regulatory change and competition. And here's the twist: a modern, digitized procurement platform is your first line of defense, because it makes the invisible visible.
Seeing in real time which supplier's GMP certificate expires within sixty days, whose quality metrics are slipping, and which one sits in a geopolitically risky zone — that's not futuristic anymore. It's a basic requirement of modern procurement.
Pharma faces a massive wave of patent losses through 2030. Estimates for 2025–2030 put $200 to $400 billion in annual revenue at risk, across roughly 200 products, including nearly 70 blockbusters. The answer? Get new products to market faster. And every internal process that slows things down — procurement included — puts revenue directly at risk.
When a procurement cycle drops from six months to three, that's not just an efficiency metric. It means you can start clinical trials three months earlier — and reach the market three months sooner.
AI integration is one of the hottest topics in pharma right now. But here's the uncomfortable part: AI is only as good as the data it has to work with.
Data from traditional procurement processes tends to be scattered across formats (spreadsheets, email, PDFs, paper), inconsistent (every department names things differently), and low quality (manual entry means errors).
You can't run predictive procurement analytics on data spread across fifteen different places. A modern S2C platform doesn't just make procurement more efficient. It's the foundation for becoming the data-driven company you're trying to build.
You don't need to roll out a new S2C platform tomorrow, but it's worth asking yourself these questions:
1. Why is procurement an executive-level question in pharma?Because procurement decisions now directly affect compliance (GMP/GxP), speed to market (procurement cycle times push back clinical trials and launch dates), and supply security. Each of these is an executive risk — it just happens to surface through procurement.
2. What is maverick spend, and why is it especially risky in pharma?It's purchasing that bypasses the official process, usually because that process is too slow. In other industries this is mostly a cost issue — missed volume discounts. In pharma it's more serious, because suppliers nobody has vetted for GMP compliance can slip in, creating recall and audit risk.
3. Why is it a problem when data lives in multiple systems?Three things happen at once: decisions slow down (every one requires manual data-gathering), mistakes become inevitable (manual copying eventually goes wrong), and visibility becomes an illusion (the monthly report is already outdated). In pharma, a mistyped batch number isn't an admin error — it's a compliance incident.
4. How does the patent cliff connect to procurement?With patents expiring through 2030, pharma companies need to bring new products to market faster to offset lost revenue. Any internal process that slows this down — including supplier qualification and contracting — directly cuts into the available market window.
5. Why can't you build AI on top of current procurement data?Because predictive analytics needs consistent, high-quality data. Typical procurement data is scattered (spreadsheets, email, PDFs), inconsistent (naming varies by department), and manually entered. Fixing the data structure isn't a step after AI — it's the prerequisite.
Procurement software evaluation checklist — A detailed checklist for evaluating software, covering:
Download the procurement software evaluation checklist here.
.png)